Axol Bioscience

Axol Bioscience

Private
RoslinHealthcare & Life Scienceshttps://axolbio.com

Last Round

Early Funding

Jan 13, 2026

Est. Valuation

$36.05M

Total Funding Raised

$15.51M

Company Overview

Axol Bioscience is a biotechnology company that provides human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of iPSC-derived cells and the delivery of laboratory services for drug discovery and disease research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

induced pluripotent stem cellsiPSCiPSC-derived cellsdisease modelingdisease in a dishdrug discovery toolsin vitro modelsstem cell companyCRO servicesdrug safety screeninggene editing servicescell line developmentiPSC-derived neuronsiPSC-derived cardiomyocytescell culture mediamulti-electrode array servicesMEA services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axol Bioscience Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Axol Bioscience Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingJan 13, 2026
GrantDec 6, 2024
Series A ExtensionApr 7, 2022
Series AMar 17, 2021
GrantDec 1, 2020
Series A
Aug 16, 2017

Key People

Founding team and executive leadership

Liam Taylor

Chief Executive Officer

Executive Team

Oliver Richardson

Chief Financial Officer

Executive Team

Axol Bioscience Investors

Notable investors and investment history

InvestorRounds
Par EquitySeries A Extension, Series A
European CommissionGrant
Roslin FoundationEarly Funding
Calculus CapitalSeries A, Series A Extension
BroadOak Capital PartnersEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    Partnering with ALS TDI and LifeArc on iPSC-derived motor neuron models.

  • Mar 3, 2026

    Developing a quantum-enabled brain-on-chip platform with multiple partners.

Axol Bioscience Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Axol Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axol Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersRoslin
Employee Range57
Year Founded2012
Last FundingJan 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.